Tech Mahindra (NSE: TECHM), a global leader in technology consulting and digital solutions, has introduced a cutting-edge pharmacovigilance (PV) autonomous solution powered by NVIDIA AI software to revolutionize drug safety management. The solution leverages agentic AI and automation to streamline pharmacovigilance workflows, enhancing accuracy, efficiency, and compliance while tackling industry challenges such as manual data processing delays and information overload.
AI-Driven Pharmacovigilance with NVIDIA AI Enterprise
Built on Tech Mahindra’s TENO framework and integrated with NVIDIA’s AI technology, the solution automates critical pharmacovigilance processes, ensuring seamless case intake, data transformation, quality control, and compliance. Using NVIDIA AI Enterprise software, including NVIDIA NeMo™, NVIDIA NIM™ microservices, and NVIDIA AI Blueprints, the solution brings LLM-powered AI agents to autonomously manage case classification, prioritization, and pharmacovigilance email verification, reducing human error and accelerating decision-making.
Nikhil Malhotra, Chief Innovation Officer & Global Head of AI and Emerging Technologies at Tech Mahindra, stated: “As the pharmaceutical industry navigates volumes of data during trials and post-launch, our collaboration with NVIDIA leverages generative AI and multi-agent systems to streamline pharmacovigilance process. Together, we are revolutionizing drug safety management and using the innovative AI-driven framework to develop multiple use cases for our global customers.”
Transforming Pharmacovigilance from Reactive to Predictive
The pharmacovigilance industry manages over 1,000 daily cases of adverse drug reactions (ADR) for major drugs. Tech Mahindra’s AI-driven PV solution addresses these challenges by:
- Automatically flagging, prioritizing, and processing ADR reports received via email, minimizing the risk of human error.
- Reducing turnaround times by up to 40%, enhancing data accuracy by 30%, and cutting operational costs by 25%.
- Ensuring regulatory compliance, improving case processing efficiency, and enabling proactive risk mitigation rather than reactive issue resolution.
John Fanelli, Vice President, Enterprise Software, NVIDIA, highlighted the role of AI in pharmacovigilance: “AI is ideal for monitoring medicines throughout their lifecycle to support safety. Integrating AI into the Tech Mahindra TENO framework with NVIDIA AI Enterprise software enhances pharmacovigilance by augmenting human capabilities to help identify potential safety issues more effectively.”
Expanding the TENO Framework for AI-Driven Healthcare Innovation
Tech Mahindra has further expanded its TENO framework by integrating NVIDIA AI Enterprise, enriching it with customized AI agents to address industry-specific challenges. The framework now includes:
- NVIDIA NeMo™ for accelerated generative AI in data collection and curation.
- Tech Mahindra’s VerifAI solution for data validation and governance.
- Distributed training and model customization capabilities to ensure continuous AI model enhancement for better decision-making.
With Tech Mahindra and NVIDIA’s AI-powered innovation, pharmacovigilance is entering a new era of automation, accuracy, and proactive drug safety management, delivering faster, smarter, and cost-effective solutions to the pharmaceutical industry.
Must Read – How Blockchain Could Revolutionize Digital Media
Join our WhatsApp News Channel for quick updates – FYI9 News WhatsApp Channel
